New Delhi, Oct 28 (NationPress) The pharma and healthcare sector in India experienced a strong surge in deal activity, totaling $3.5 billion in Q3 2025, as revealed in a report on Tuesday.

According to Grant Thornton Bharat’s Pharma and Healthcare Dealtracker report, the sector recorded a remarkable 72 transactions, reflecting a 28 percent increase in volume and a staggering 166 percent growth in value quarter on quarter.

This quarter's activity included three IPOs worth $428 million and one QIP valued at $88 million, as per the report.

When excluding public market transactions, private deals accounted for $3 billion across 68 transactions, indicating a significant rebound in investor interest.

The report highlighted that the upswing was propelled by seven high-value deals totaling $2.6 billion, showcasing renewed investor confidence in scale and consolidation across the pharma, biotech, and hospital sectors.

“Q3 witnessed a resurgence in deal activity, supported by a healthy mix of scale, capabilities, and innovation-driven investments,” stated Bhanu Prakash Kalmath S J, Partner and Healthcare Industry Leader at Grant Thornton Bharat.

He further noted, “The growing momentum in pharma and biotech, backed by strategic consolidations, indicates heightened confidence in India’s life sciences potential.”

Moreover, the report indicated that mergers and acquisitions (M&A) activities surged in Q3, recording 36 deals valued at $2.5 billion, which marks a 57 percent increase in volume and an impressive 12.2x leap in value compared to the previous quarter.

In the healthcare and pharma sectors, Private Equity saw 32 deals worth $425 million in Q3 2025, reflecting a 3 percent decline in volumes and a 27 percent drop in value from the previous quarter.

Hospitals recorded 19 deals worth $264 million. The trend of multi-specialty consolidation accelerated in western India and NCR, while single-specialty areas such as dialysis, IVF, oncology, and women and childcare drove the transaction volumes, as stated in the report.

“The ongoing investor enthusiasm for hospitals, single-specialty formats, and wellness platforms underscores the sector's shift towards clinical excellence, broader reach, specialization, and technology-driven consumer-centric care. Despite global uncertainties, the steady flow of capital demonstrates the long-term resilience and structural growth of India’s healthcare ecosystem,” asserted Bhanu Prakash.